Mi
Mimetogen
Morgantown WVFounded 201220 employees
Private CapbiotechAcquiredOphthalmology
Platform: MIM-D3 DryEye
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
3
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| MIM-1147 | MIM-1147 | Phase 2 | 1 | TYK2 | AngelmanNB | ||
| MIM-9797 | MIM-9797 | Phase 2/3 | 2 | BCL-2 | NB | ||
| MIM-9595 | MIM-9595 | Preclinical | 2 | TIM-3 | RSV | ||
| Mirisertib | MIM-9956 | Phase 3 | 4 | CD19 | FabryADPKD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)